Calbiotech Cardiolipin IgA Elisa Kit

Product Description

Measurement of IgG, IgM and IgA cardiolipin autoantibodies (aCL) by EIA is the standard procedure for thedetection of antiphospholipid antibodies (aPL) in patients with suspected antiphospholipid syndrome (APS).High aCL concentrations are associated with increased risk of venous and arterial thrombosis, recurrentpregnancy loss and thrombocytopenia. Patients with the anti-cardiolipin syndrome have one of the aboveclinical features and have antibodies to cardiolipin and/or a positive lupus anticoagulant test. The antibodiespresent to cardiolipin may be of the IgG, IgA, IgM isotypes. Testing for the various antibody isotypes tocardiolipin aid in diagnosis of the anti-phospholipid syndrome in patients with SLE or lupus-like disorders.Binding of aCL to CL in patients with autoimmune diseases is dependent on the presence of the cofactorbeta-2-glycoprotein I (beta2-GPI); this binding is independent of beta-2-GPI in patients with infectiousdiseases (e.g., syphilis, tuberculosis). Recognition of the role of beta-2- GPI in the binding of aCL led todevelopment of assay for direct measurement of beta-2-GPI autoantibodies using beta-2-GPI as antigen,allowing a clear distinction between beta-2-GPI autoantibodies and those that bind to CL alone.